Effects of Coenzyme Q10 in PSP and CBD
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 6/17/2018 |
| Start Date: | January 2004 |
| End Date: | September 2005 |
Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study
To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients
with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive
supranuclear palsy (PSP) ).
with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive
supranuclear palsy (PSP) ).
Inclusion Criteria:
- Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were
diagnosed within the past 5 years
- Age > 40
- Subjects receiving anticholinergics, amantadine, dopamine agonists,
carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days
prior to baseline visit.
- Patients agreeable to participate in the study.
Exclusion Criteria:
- Prior or concurrent therapy with anticholinergics, amantadine,a dopamine
agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
- Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
- History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue
transplant.
- Previous use of coenzyme Q10 within 60 days of the baseline visit.
We found this trial at
1
site
Lahey Clinic When Frank Lahey, MD, founded a group practice in 1923, his vision was...
Click here to add this to my saved trials
